Abstract: Epidemiological studies indicate that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, play a role in inhibition of several human neoplasia including breast cancer. In this study, chemopreventive effects of atorvastatin in N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats were evaluated. Atorvastatin was administered in the diet at two concentrations: 10 mg/kg (ATOR 10) and 100 mg/kg (ATOR 100). Atorvastatin treatment began 8 days prior to carcinogen administration and subsequently continued for 15 weeks till the end of the experiment. Atorvastatin at a higher dose suppressed tumor frequency by 80.5% (P = 0.0008) and tumor incidence by 49.5% (P = 0.015), and extended latency period by 14 days (P = 0.076) when compared to the control group. Atorvastatin at a lower dose did not significantly alter tumor parameters in comparison with the control group. In the specimens of mammary tumors, atorvastatin (in the ATOR 100 group) significantly decreased mRNA expression of Bcl-2 gene but non-significantly increased Bax mRNA expression compared to control group. Atorvastatin administration did not alter serum concentration of triacylglycerols, total cholesterol, and LDL cholesterol in comparison with controls. This study is the first report on tumor suppressive effect of atorvastatin in rat mammary carcinogenesis.
Introduction
The aim of chemopreventive trials is to find an efficient substance that can be administered for a long period with minimum adverse effects. Drugs with pleiotropic effects, primarily used in treatment of other disorders, with anticarcinogenic efficacy, e.g., non-steroidal antiinflammatory drugs, selective estrogen receptor modulators (Chamilova et al. 2001; Kubatka et al. 2002) , antidiabetics, or statins, are preferable. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, are substances commonly used for hypercholesterolemia treatment but they were shown to decrease the incidence of adverse cardiovascular events, including myocardial infarction, stroke, atrial fibrillation, and renal dysfunction.
Recent in vitro studies proved direct or indirect effect of statins in cell proliferation, differentiation, and apoptosis regulation and therefore statins draw attention of clinical and experimental oncologists. Statins inhibit dolichol-, farnesyl-and geranylgeranyl pyrophosphate production, and block tumor cell proliferation through mevalonate (Rao et al. 1998; Denoyelle et al. 2001) . Lovastatin has been demonstrated to stabilize the cell cycle kinase inhibitors p21 and p27 and to induce G1 arrest in breast cancer cell lines (Rao et al. 1998) . Cerivastatin has been shown to inhibit Rasand Rho-mediated cell growth (Denoyelle et al. 2001) . Proposed mechanisms for statin-mediated apoptosis include an upregulation of proapoptotic protein expression (Bax, Bim) together with decreased antiapoptotic protein expression (Bcl-2) (Jiang et al. 2004) , or activation of caspase-3, caspase-8, and caspase-9 (Cafforio et al. 2005) . Angiogenesis plays an important P. Kubatka et al. role in the growth of primary tumors and metastasis. High-dose of cerivastatin decreased tumor vascularisation by 51% in murine Lewis lung cancer model (Weis et al. 2002) . Statins have been shown to decrease vascular endothelial growth factor production and to inhibit capillary formation (Park et al. 2002) . Statins may impair the metastatic potential of tumor cells, too. Statins reduced endothelial leukocyte adhesion molecule E-selectin (Nubel et al. 2004 ) and matrix metalloproteinase-9 expression (Wang et al. 2000) . Fluvastatin and lovastatin inhibited liver tumorigenesis and liver metastasis in pancreatic cancer cells (Kusama et al. 2002) and atorvastatin decreased melanoma cell metastasis (Collisson et al. 2003) . Several epidemiological (Downs et al. 1998; Blais et al. 2000; Poynter et al. 2005; Shannon et al. 2005) and clinical studies (Kawata et al. 2001; Minden et al. 2001; Katz et al. 2005 ) have demonstrated the antitumor potential of statins in various cancer types. There are also some clinical studies with statins focused on breast cancer research. A multicenter prospective cohort study including 7,528 Caucasian older women in USA showed a 68% lower breast cancer risk in lipidlowering drug users. Further adjustment for hormone use, family history of breast cancer, mammography screening, or other risk factors did not alter the results (Cauley et al. 2003) . A neoadjuvant study of fluvastatin was conducted in women diagnosed with DCIS or stage 1 breast cancer. The drug administered for 3-6 weeks before surgery reduced tumor proliferation and increased apoptotic activity in high-grade, stage 0/1 breast cancers (Garwood et al. 2010) . In another study of total 2,932 cases of primary invasive breast cancer, the cholesterol-lowering drugs (including statins) users had significantly lower risk of estrogen and progesterone receptor-positive breast cancer compared to non-users (Fagherazzi et al. 2010) . On the other hand, the study with overweight or obese postmenopausal women did not reveal association between the use of statins and breast cancer risk. However, compared to non-users, obese women who used hydrophobic statins had an elevated risk of progesterone receptor-negative breast cancer (Eaton et al. 2009 ). Association between long-term statin use and breast cancer risk deserves thus further investigation.
Original experimental studies are necessary, which would evaluate possible tumor suppressive effects of statins in mammary carcinogenesis. The aim of this work was to evaluate the chemopreventive effect of atorvastatin in the model of mammary carcinogenesis in female rats. Side effects of atorvastatin after prolonged treatment in rats and selected parameters of apoptosis gene expression in mammary tumors were evaluated.
Material and methods
Female rats of Sprague-Dawley strain obtained from AnLab (Prague, Czech Republic) aged 30-34 days were used in the experiment. The animals were adapted to standard vivarium conditions with temperature of 23 ± 2 • C, relative humidity 40-60%, artificial regimen light : dark (12 : 12 h) (lights on from 6 a.m., light intensity 150 lux per cage). Animals were randomly assigned to one of the three experimental groups: (1) control group without chemoprevention; (2) chemoprevention with atorvastatin at a concentration of 10 mg/kg in the chow (ATOR 10); (3) chemoprevention with atorvastatin at a concentration of 100 mg/kg in the chow (ATOR 100). Each experimental group consisted of 20 animals. The chow containing atorvastatin calcium (Lipitor) synthesized by Pfizer (Pfizer Inc., New York, USA) was prepared by SSNIFF Spezialdiäten GmbH (Soest, Germany). The assumed average daily dose of atorvastatin per rat in the group ATOR 10 is equivalent to the daily dose of Lipitor (40 mg/day) administered in patients with hypercholesterolemia. Based on our previous experience with drug dosing in rats (many pharmaceuticals in rats demonstrate different pharmacokinetics and pharmacodynamics than in humans) it was necessary to use high doses of atorvastatin in the group ATOR 100 to uncover its expected antineoplastic effect in this experiment. Mammary carcinogenesis was induced by N-methyl-N-nitrosourea (NMU) (Sigma, Deisenhofen, Germany) administered intraperitoneally in single dose (50 mg/kg body weight) on the 40 th postnatal day. Chemoprevention with atorvastatin began 8 days before NMU administration and lasted until the end of the experiment -15 weeks after carcinogen application. From 4 th week after NMU, the animals were weekly weighed and palpated in order to register the presence, number, location, and size of each palpable tumor.
In the last week of the experiment, the animals were quickly decapitated, the blood from each animal was collected, mammary tumors were excised and tumor size was recorded. At autopsy, macroscopic changes in selected organs (liver, kidney, stomach, intestine and lung) were evaluated. Tissue samples of each mammary tumor were divided into two sections, the first one was fixed in 10% formol and prepared for histological analysis, and the second one was frozen in liquid nitrogen for later evaluation of apoptosis gene expression. Specimens for histopathological examination were embedded in paraffin using conventional automated systems. The blocks were cut to obtain 4 to 5 µm-thick sections and were stained with hematoxylin-eosin. The tumors were classified according to the criteria for the classification of rat mammary tumors (Russo & Russo 2000) . The basic parameters of mammary carcinogenesis (tumor incidence, frequency, latency, and volume) in each group were evaluated. The effect of atorvastatin on food, water intake, and final body weight was monitored. Food and water intake was monitored during 24 hours in 7 th and 14 th week of the experiment. Serum lipid parameters were evaluated by automatic biochemical analyzer Olympus AU 640 (Olympus Optical, Tokyo, Japan). Total RNA was isolated using Trizol (Gibco/BRL), purified using RNeasy Mini Kit (Qiagen) and transcribed using Superscript II (Invitrogen) reverse transcriptase and oligoT primers (Invitrogen). qRT-PCRs were performed by iCycler iQ Real-Time PCR Detection System (BioRad) in 25 µL reaction volume containing: 1 × iQ TM SYBR Green Supermix (0.2 mM dNTP, 3 mM MgCl2), 0.5 µM forward and reverse primer and 2 µL of cDNA. For bcl-2 and β-actine detection, forward primers TGCACCTGACGCCCTTCAC and ACCAACTGGGACGACATGGAGAAAATC as well as reverse primers AGACAGCC-AGGAGAAATCAAACAG and GTAGCCGCGCTCGGTGAGGATCTTCAT, respectively, were used. The bax gene was determined by the primers designed by SuperArray (SuperArray Biosciences). The reac- Malignant lesions I-C 15 11 4 I-C,P 13 10 3 I-P 6 2 2
Total number 49 32 10 a I-C -invasive cribriform carcinoma; I-C,P -invasive cribriform and papillary carcinoma; I-P -invasive papillary carcinoma; I-P,C -invasive papillary and cribriform carcinoma; IS-P,C -in situ papillary and cribriform carcinoma; I-C,CO -invasive cribriform and comedo carcinoma; I-T,C -invasive tubular and cribriform carcinoma; IS-C,CO -in situ cribriform and comedo carcinoma; IS-C -in situ cribriform carcinoma; IS-P+IDP -in situ papillary carcinoma and intraductal proliferation; IDP -intraductal proliferation; PAP -papilloma; TA -tubular adenoma; TA+PAP -tubular adenoma and papilloma. Dominant type in mixed tumors is the first in the order. • C for 7 min followed by melting curve analysis to confirm amplification of the desired single and specific product. The calculated resulting relative expressions (evaluated by the method of standard curve) of bcl-2 and bax genes were normalized to relative β-actin expression (bcl-2/β-actin and bax/β-actin).
Statistical analysis of tumor growth parameters was performed by Mann-Whitney U-test, one-way analysis of variance, or Kruskal-Wallis test. Tumor volume was calculated according to formula: V = π(S1) 2 · S2/12; S1 and S2 are tumor diameters (S1 < S2). The mRNA expression was analyzed by F-test followed by Kruskal-Wallis test to determine differences between all independent groups. Statistical differences between groups were evaluated using the MannWhitney U-test.
Results
Atorvastatin administered at a lower dose in the experimental group ATOR 10 non-significantly decreased the incidence of mammary neoplasia by 11.5 % (P = 0.54) and the frequency by 38% (P = 0.38) in comparison with animals in the control group. The latency in this group was reduced by 1.5 day when compared to the controls. Atorvastatin inhibited rat mammary carcinogenesis in a dose-dependent manner. In experimental group ATOR 100, atorvastatin decreased the incidence by 49.5% (P = 0.015), frequency by 80.5% (P = 0.0008), and lengthened the latency by 14 days in comparison with the control animals. Atorvastatin in both groups ATOR 10 and ATOR 100 non-significantly increased tumor volume by 100% (P = 0.16) or 44% (P = 0.69), respectively, in comparison with the control group. The evaluation of this parameter in this study was impeded by occurrence of numerous new tumors with small volumes in control group. On the other hand, cumulative tumor volume in the group ATOR 100 showed apparent decrease by 70.5% when compared to the controls. Table 1 summarizes the effects of atorvastatin on rat mammary carcinogenesis. In order to demonstrate apparent chemopreventive effects of atorvastatin in the group ATOR 100, we have analyzed the continuous development of tumor incidence and frequency in animals (Figs 1 and 2) .
The histopathological classification of all mammary tumors is summarized in Table 2 . A histopathological analysis of mammary tumors has revealed a shift in the rate of poorly differentiated and well differentiated invasive mammary carcinomas after atorvastatin treatment. Invasive carcinomas in the group ATOR 100 demonstrated higher grade of differentiation compared to carcinomas in the control group. The comparison of some histomorphological characteristics of mammary tumors between control group and ATOR 100 group is outlined in Figure 3 .
With regard to evaluation of mRNA expression in tumors (Fig. 4) , the lower concentration of atorvastatin (ATOR 10) did not significantly change the mRNA expression of both anti-apoptotic bcl-2 (P = 0.251) and pro-apoptotic bax (P = 0.489) genes. On the contrary, the higher concentration of atorvastatin (ATOR 100) significantly decreased mRNA expression of bcl- 2 (P=0.039) and non-significantly increased the bax mRNA expression (P = 0.078) compared to data from control group.
At autopsy, no macroscopic changes due to longterm atorvastatin administration in the selected organs -liver, kidney, stomach, intestine and lung -were observed. The evaluation of final body weight in rats revealed significant increase by 17 g (P = 0.0278) in ATOR 10 group in comparison with control animals. No changes in the final body weight in ATOR 100 group when compared to controls were found. Atorvastatin did not significantly change food and water intake in animals when compared to controls. Average daily food intake (g) per rat in experimental groups was as follows: CONT -18.83 ± 0.46; ATOR 10 -18.84 ± 0.61; ATOR 100 -19.78 ± 0.47. Daily average dose of atorvastatin per rat was 0.19 mg in the group ATOR 10 and 1.98 mg in group ATOR 100.
As shown in Table 3 , atorvastatin in both groups did not significantly change triacylglycerols, total cholesterol, and LDL-cholesterol serum concentration when compared to the control group.
Discussion
This study is, according to our knowledge, the first report on tumor suppressive effects of atorvastatin, i.e. a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in experimental rat mammary carcinogenesis. With exception of tumor volume, a substantial antitumor effect of atorvastatin administered at a concentration of 100 mg/kg of chow was recorded in all evaluated parameters in mammary carcinogenesis in female rats. Similarly, in our recent study simvastatin administered in the diet at a dose of 180 mg/kg significantly reduced mammary tumor frequency by 80.5% and incidence by 58.5% when compared to controls (Kubatka et al. 2011) . In 1,2-dimethylhydrazine-induced colon car- cinogenesis in ICR mice, simvastatin and pravastatin significantly reduced tumor frequency (Narisawa et al. 1994) . Pravastatin has been shown to reduce the incidence and volume of N-nitrosomorpholine-induced rat hepatic neoplastic nodules (Tatsuta et al. 1998 ) and NMU-induced rat colon carcinogenesis (Narisawa et al. 1996) . Moreover, several studies in rodents have also shown preventive effects of lipophilic statins on the growth of diverse tumors (Hawk et al. 1996; Inano et al. 1997; Kikuchi et al. 1997; Matar et al. 1998) . Despite the strong evidence on statins' antineoplastic effects in several animal models in above-mentioned papers, there are also experimental data suggesting a minimal tumor-suppressive activity or even potential carcinogenicity of these drugs. Lubet et al. (2009) reported on dietary administered atorvastatin and lovastatin either as single agents or in combination with suboptimal doses of tamoxifen or rexinoid bexarotene in the prevention of NMU-induced rat mammary carcinogenesis. In this experiment atorvastatin alone (125 and 500 mg/kg) did not significantly alter incidence and frequency of mammary tumors. Atorvastatin (500 mg/kg diet) administered in combination with tamoxifen or bexarotene minimally altered efficacy of these drugs. Similarly, lovastatin (100 and 400 mg/kg) yielded a limited oncostatic activity administered alone or in combination with tamoxifen or bexarotene. The results of both above-mentioned experiments with atorvastatin or lovastatin (Lubet et al. 2009 ) are in strong contradiction with antineoplastic effects of atorvastatin or simvastatin in rat mammary carcinogenesis observed by our group. Another experimental data suggested potential carcinogenicity of statins. Simvastatin administered at a dose about 250-times higher than the dose normally used to hypercholesterolemia treatment induced thyroid hypertophy and follicular cell adenomas in rats (Smith et al. 1991) . Similarly, lovastatin administration at high doses was associated with higher incidence of hepatocellular and pulmonary cancers in animal models (MacDonald et al. 1988 ). In another study, an association between fluvastatin and higher risk of thyroid neoplasms and forestomach papillomas in rodents was found (Robison et al. 1994) .
With regard to clinical research, only few consistent associations between statins and cancer incidence were observed (Boudreau et al. 2010 ). There are reports from clinical trials and observational studies that evaluated all cancers (Jacobs et al. 2011) or site-specific cancer of breast (Woditska et al. 2010) , colorectum (Yano et al. 2008) , lung (Khurana et al. 2007 ), prostate (Bonovas et al. 2008) , and reproductive organs (Yu et al. 2009 ) associated with the statins use. Data on effects of statins on cancer prognosis and secondary prevention are lacking, with the exception of consistent evidence that statins are associated with reduced risk of advanced prostate cancer. Statins appear safe in relation to cancer risk but any preventive effect in humans remains to be established.
In our experiment, a significant antineoplastic effect of atorvastatin in rat mammary carcinogenesis should be explained by several above-mentioned mechanisms. Data from experimental in vitro studies demonstrated evident link between atorvastatin use and apoptosis induction in various human cells. The treatment of vascular smooth muscle cells with atorvastatin and simvastatin inhibited Bcl-2 expression and induced activation of caspase-9 (Blanco-Colio et al. 2002) . In another experiment, atorvastatin-induced apoptosis in activated stellate cells was related to increased activity of both caspase-9 and -3 and a Bid protein (Aprigliano et al. 2008) . In human cancer cell lines, atorvastatin showed significant proapoptotic activities in colon (Xiao et al. 2008 ) and bladder (Kamat & Nelkin 2005) cancer. In order to point out the proapoptotic effects of atorvastatin in our study, the specimens of mammary tumors from all experimental groups were evaluated for mRNA expression of anti-apoptotic bcl-2 and pro-apoptotic bax genes. In this regard, proapoptotic shift in Bax/Bcl-2 mRNA expression ratio induced by atorvastatin (100 mg/kg diet) in our experiment was confirmed.
Although the favorable effects of statins in the prevention of cardiovascular diseases resulting from hypercholesterolemia are well established, increasing evidence suggests that these drugs exert pleiotropic effect, independent of cholesterol reduction. Our study points out that antineoplastic effect of atorvastatin in rat mammary carcinogenesis is independent from its effects on plasma lipid metabolism, i.e. atorvastatin in both concentrations did not change serum triacylglycerols, total cholesterol, and LDL-cholesterol. Similarly, inhibitory effect of pravastatin against colon carcinogenesis in rats was not related to the cholesterol-lowering effect of this agent (Narisawa et al. 1996) . And similarly in another experiment of rat mammary carcinogenesis mentioned above, atorvastatin and lovastatin did not decrease serum triacylglycerols in animals, but in contrary to previous studies, drugs did not demonstrate significant antineoplastic effects in mammary gland carcinogenesis (Lubet et al. 2009 ).
Due to antimitotic, antiangiogenic, antimetastatic, and pro-apoptotic effects, statins may represent a novel medical approach for cancer risk reduction or treatment. Future large clinical trials should definitively answer the question about statins' role in carcinogenesis. Several of the ongoing studies have given initial promising results. The results of our study clearly pointed to atorvastatin's favorable effects in experimental rat mammary carcinogenesis and gave atorvastatin a chance to become a substance with chemopreventive efficacy in various neoplasia including breast cancer. Our experiment provided a rationale for the potential use of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin in women, who need the treatment of hypercholesterolemia and are at high risk of breast cancer as well. 
